Inicia sesión Registrate Mi Biblioteca idioma

Idioma

biblioteca idioma abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.

Enfermedad de Parkinson

32316 ARTíCULOS , VIENDO DEL 31696 AL 31710

PUBMED

Exercise in Parkinson's disease: Experimental-induced pain sensitivity is reduced already after short term training.

Mylius V.

Eur J Pain. 2019 Oct;23(9):1585. doi: 10.1002/ejp.1468. Epub 2019 Aug 28. No abstract available.

0

0

0

PUBMED

Oral Silica Nanoparticles Lack of Neurotoxic Effects in a Parkinson's Disease Model: A Possible Nanocarrier?

Guzman-Ruiz MA, de La Mora MB, Torres X, Meza C, Garcia E, Chavarria A.

IEEE Trans Nanobioscience. 2019 Oct;18(4):535-541. doi: 10.1109/TNB.2019.2934074. Epub 2019 Aug 8.

0

0

0

PUBMED

Discussing sexuality with Parkinson's disease patients: a multinational survey among neurologists.

de Rooy FBB, Buhmann C, Schönwald B, Martinez-Martin P, Rodriguez-Blazquez C, Putter H, Elzevier HW, van der Plas AA.

J Neural Transm (Vienna). 2019 Oct;126(10):1273-1280. doi: 10.1007/s00702-019-02053-5. Epub 2019 Aug 8.

0

0

0

PUBMED

Relationship between 25-Hydroxyvitamin D, bone density, and Parkinson's disease symptoms.

Zhang HJ, Zhang JR, Mao CJ, Li K, Wang F, Chen J, Liu CF.

Acta Neurol Scand. 2019 Oct;140(4):274-280. doi: 10.1111/ane.13141. Epub 2019 Aug 6.

0

0

0

PUBMED

The therapeutic effect of deep brain stimulation on olfactory functions and clinical scores in Parkinson's disease.

Saatçi Ö, Yılmaz NH, Zırh A, Yulug B.

J Clin Neurosci. 2019 Oct;68:55-61. doi: 10.1016/j.jocn.2019.07.055. Epub 2019 Aug 2.

0

0

0

PUBMED

Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease.

Chekani F, Holmes HM, Johnson ML, Chen H, Sherer JT, Aparasu RR.

J Psychiatr Res. 2019 Oct;117:116-121. doi: 10.1016/j.jpsychires.2019.07.005. Epub 2019 Jul 26.

0

0

0

PUBMED

Probabilistic sweet spots predict motor outcome for deep brain stimulation in Parkinson disease.

Dembek TA, Roediger J, Horn A, Reker P, Oehrn C, Dafsari HS, Li N, Kühn AA, Fink GR, Visser-Vandewalle V, Barbe MT, Timmermann L.

Ann Neurol. 2019 Oct;86(4):527-538. doi: 10.1002/ana.25567.

0

0

0

PUBMED

Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification.

Bjørklund G, Hofer T, Nurchi VM, Aaseth J.

J Inorg Biochem. 2019 Oct;199:110717. doi: 10.1016/j.jinorgbio.2019.110717. Epub 2019 May 19.

0

0

0

PUBMED

5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: Implications for Parkinson's disease.

Badillo-Ramírez I, Saniger JM, Rivas-Arancibia S.

Neurochem Int. 2019 Oct;129:104514. doi: 10.1016/j.neuint.2019.104514. Epub 2019 Jul 29. Review.

0

0

0

PUBMED

Orexins alleviate motor deficits via increasing firing activity of pallidal neurons in a mouse model of Parkinson's disease.

Wang Y, Chen AQ, Xue Y, Liu MF, Liu C, Liu YH, Pan YP, Diao HL, Chen L.

Am J Physiol Cell Physiol. 2019 Oct 1;317(4):C800-C812. doi: 10.1152/ajpcell.00125.2019. Epub 2019 Jul 31.

0

0

0

PUBMED

Regional transcriptional architecture of Parkinson's disease pathogenesis and network spread.

Freeze B, Pandya S, Zeighami Y, Raj A.

Brain. 2019 Oct 1;142(10):3072-3085. doi: 10.1093/brain/awz223.

0

0

0

PUBMED

Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinson's disease by suppressing the activation of the AKT and NF-κB signaling pathways.

Li Y, Zeng Y, Meng T, Gao X, Huang B, He D, Ran X, Du J, Zhang Y, Fu S, Hu G.

Int Immunopharmacol. 2019 Oct;75:105739. doi: 10.1016/j.intimp.2019.105739. Epub 2019 Jul 24.

0

0

0

PUBMED

IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.

Liu Z, Qiu AW, Huang Y, Yang Y, Chen JN, Gu TT, Cao BB, Qiu YH, Peng YP.

Brain Behav Immun. 2019 Oct;81:630-645. doi: 10.1016/j.bbi.2019.07.026. Epub 2019 Jul 24.

0

0

0

PUBMED

Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease.

Grozdanov V, Bousset L, Hoffmeister M, Bliederhaeuser C, Meier C, Madiona K, Pieri L, Kiechle M, McLean PJ, Kassubek J, Behrends C, Ludolph AC, Weishaupt JH, Melki R, Danzer KM.

Ann Neurol. 2019 Oct;86(4):593-606. doi: 10.1002/ana.25557. Epub 2019 Aug 15.

0

0

0

PUBMED

Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.

Ceccarini J, Casteels C, Ahmad R, Crabbé M, Van de Vliet L, Vanhaute H, Vandenbulcke M, Vandenberghe W, Van Laere K.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2348-2357. doi: 10.1007/s00259-019-04445-x. Epub 2019 Jul 24.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo HONcode Logo WIS

En colaboración con:

Zambon Neuroacademy